Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Unspecified Adult Solid Tumor, Protocol Specific 184Mesothelioma, Malignant 183Mesothelioma 145Solid Tumor 135Retinoblastoma 96Solid Tumors 86Advanced Solid Tumor 60Advanced Solid Tumors 50Solid Tumor, Adult 47Hematopoietic and Lymphatic System Neoplasm 47Carcinoma, Non-Small-Cell Lung 42Lung Neoplasms 33Sarcoma 28Hematopoietic and Lymphoid System Neoplasm 23Small Cell Lung Carcinoma 21Pancreatic Neoplasms 20Stomach Neoplasms 19Neuroblastoma 19Melanoma 19Carcinoma, Renal Cell 19Ovarian Neoplasms 18Neoplasms 17Wilms Tumor 15Colorectal Neoplasms 15Breast Neoplasms 15Osteosarcoma 13Solitary Fibrous Tumor, Pleural 12Rhabdomyosarcoma 12Refractory Solid Tumors 12Esophageal Neoplasms 12

Interventions

Imatinib Mesylate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Metastatic Solid Tumors. × Other solid neoplasm × Clear all
NCT00159016 2011-04-28

Role of Glivec in Patients With Tumor Cells Positive for C-kit or PDGFR; a Multi Center Study.

Hadassah Medical Organization

Phase 2 Withdrawn
100 enrolled
Other solid neoplasm

Metastatic Solid Tumors.

Data powered by HemOnc (CC BY 4.0) Colophon âš¡